Travere Therapeutics (TVTX) Inventory Average (2014 - 2026)

Travere Therapeutics has reported Inventory Average for 13 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Inventory Average rose 20.72% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $6.1 million (up 20.72% YoY), and the FY2025 full-year result was $6.0 million, down 22.65% from the prior year.
• Inventory Average for Q1 2026 stood at $6.1 million, up from $5.7 million in the prior quarter.
• The five-year high for Inventory Average was $19.8 million in Q3 2023, with the low at $4.0 million in Q2 2025.
• Historically, Inventory Average has averaged $7.7 million across 5 years, with a median of $6.2 million in 2024.
• Annual changes were most pronounced in 2023 — Inventory Average soared 164.84% — and 2024, when it slumped 68.81%.
• Travere Therapeutics' Inventory Average stood at $5.9 million in 2022, then jumped by 155.36% to $15.1 million in 2023, then tumbled by 58.4% to $6.3 million in 2024, then slipped by 9.02% to $5.7 million in 2025, then grew by 7.07% to $6.1 million in 2026.
• The last three Inventory Average figures came in at $6.1 million (Q1 2026), $5.7 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.